Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 18 articles: HTML format

Single Articles

December 2021
1. SHARMA V, Kumar A
   Carcinoma en Cuirasse.
   N Engl J Med. 2021;385:2562.
   PubMed    
   
   
   
2. KALINSKY K, Barlow WE, Gralow JR, Meric-Bernstam F, et al
   21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
   N Engl J Med. 2021;385:2336-2347.
   PubMed     Abstract available
   
   
   October 2021
3. TUTT ANJ, Garber JE, Geyer CE Jr
   Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply.
   N Engl J Med. 2021;385:1440.
   PubMed    
   
   
   
4. HOSHI A, Bando H, Sekine I
   Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
   N Engl J Med. 2021;385:1439-1440.
   PubMed    
   
   
   
5. NOZAWA K, Yoshimura A, Iwata H
   Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
   N Engl J Med. 2021;385:1439.
   PubMed    
   
   
   September 2021
6. BOSE R, Ma CX
   Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance.
   N Engl J Med. 2021;385:1241-1243.
   PubMed    
   
   
   July 2021
7. GOODWIN PJ
   Extended Aromatase Inhibitors in Hormone-Receptor-Positive Breast Cancer.
   N Engl J Med. 2021;385:462-463.
   PubMed    
   
   
   
8. GNANT M, Fitzal F, Rinnerthaler G, Steger GG, et al
   Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
   N Engl J Med. 2021;385:395-405.
   PubMed     Abstract available
   
   
   
9. BARDIA A, Hurvitz SA, Rugo HS
   Sacituzumab Govitecan in Metastatic Breast Cancer. Reply.
   N Engl J Med. 2021;385:e12.
   PubMed    
   
   
   
10. GANGULY S, Gogia A
    Sacituzumab Govitecan in Metastatic Breast Cancer.
    N Engl J Med. 2021;385:e12.
    PubMed    
    
    
    June 2021
11. TUTT ANJ, Garber JE, Kaufman B, Viale G, et al
    Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
    N Engl J Med. 2021 Jun 3. doi: 10.1056/NEJMoa2105215.
    PubMed     Abstract available
    
    
    April 2021
12. BARDIA A, Hurvitz SA, Tolaney SM, Loirat D, et al
    Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    N Engl J Med. 2021;384:1529-1541.
    PubMed     Abstract available
    
    
    March 2021
13. BURSTEIN HJ
    Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply.
    N Engl J Med. 2021;384:1176-1177.
    PubMed    
    
    
    
14. COPUR MS
    Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    N Engl J Med. 2021;384:1176.
    PubMed    
    
    
    January 2021
15. DORLING L, Carvalho S, Allen J, Gonzalez-Neira A, et al
    Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMoa1913948.
    PubMed     Abstract available
    
    
    
16. NAROD SA
    Which Genes for Hereditary Breast Cancer?
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMe2035083.
    PubMed    
    
    
    
17. HU C, Hart SN, Gnanaolivu R, Huang H, et al
    A Population-Based Study of Genes Previously Implicated in Breast Cancer.
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMoa2005936.
    PubMed     Abstract available
    
    
    December 2020
18. BURSTEIN HJ
    Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    N Engl J Med. 2020;383:2557-2570.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: